Search clinical trials for: Crizotinib plus axitinib

Total 5924 results

Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Pfizer

Completed

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
Pfizer

Completed

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Solid Tumors

United States, Taiwan, Japan, Korea, Republic of, Russian Federation, Hungary, France, Czechia, Germany, Italy, United Kingdom
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Hepatobiliary Neoplasm | Liver Neoplasm | Biliary Tract Neoplasms

China
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-Small Cell Lung Cancer

United States
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Pfizer

Completed

A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation

Healthy

Belgium
ZHOU FANGJIAN
Pfizer

Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell Carcinoma | Neoadjuvant

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Bart Neyns
Pfizer

Completed

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (AxiGII)

Glioblastoma Multiforme

Belgium
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
University Hospital, Bordeaux

Completed

Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors (EVAX)

Carcinoma, Renal Cell | Malignant Advanced Solid Tumors

France
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

The Efficacy and Safety of KN046 Combined With Axitinib

NSCLC

China
Wuhan Union Hospital, China

Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)

Colorectal Cancer | Chemotherapy | Angiogenesis
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted Therapy

China
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Enrolling by invitation

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)

Esophageal Squamous Cell Carcinoma (ESCC)

Taiwan
Samsung Medical Center

Completed

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

c-MET Positive Gastric Cancer

Korea, Republic of
Pfizer

Completed

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Renal Impairment

United States
Pfizer

Completed

Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule

Healthy

Belgium
Pfizer

Completed

Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers

Healthy

Belgium
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Unknown

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Hepatocellular Carcinoma | Liver Transplant

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Shanxi Province Cancer Hospital

Unknown

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

Brain Metastases
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
Pfizer

Completed

A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers

Healthy

Belgium
Yonsei University

Completed

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NSCLC
Pfizer

Completed

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

Healthy Volunteer

United States
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
University of Milano Bicocca

Completed

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Anaplastic Large Cell Lymphoma, ALK-Positive

Italy
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
Jun Zhu
Peking University First Hospital; Peking University People's Hospital; Peking... and other collaborators

Withdrawn

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Systemic Anaplastic Large-Cell Lymphoma

China
National Cheng-Kung University Hospital
Kaohsiung Medical University; Kaohsiung Veterans General Hospital.; Chi Mei Medical...

Recruiting

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Endometrial Cancer Recurrent

Taiwan
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Pfizer

Completed

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Advanced Cancer

United States
Pfizer

Completed

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

Healthy

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

China
West China Hospital

Active, not recruiting

Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

Carcinoma, Renal Cell | Immunotherapy | Fumarate Hydratase Deficiency

China

Search clinical trials for: Crizotinib plus axitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations